149 related articles for article (PubMed ID: 38112220)
1. No indication of aberrant neutrophil extracellular trap release in indolent or advanced systemic mastocytosis.
Rosell A; Karlström C; Dahlin JS; Boey D; Klimkowska M; Ax K; Thålin C; Ungerstedt J
Scand J Immunol; 2024 Jan; 99(1):e13333. PubMed ID: 38112220
[TBL] [Abstract][Full Text] [Related]
2. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
3. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
4. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre.
Hermans MAW; Rietveld MJA; van Laar JAM; Dalm VASH; Verburg M; Pasmans SGMA; Gerth van Wijk R; van Hagen PM; van Daele PLA
Eur J Intern Med; 2016 May; 30():25-30. PubMed ID: 26809706
[TBL] [Abstract][Full Text] [Related]
5. [Tryptase: A practical guide for the physician].
Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S
Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042
[TBL] [Abstract][Full Text] [Related]
6. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
7. Levels of mast-cell growth factors in plasma and in suction skin blister fluid in adults with mastocytosis: correlation with dermal mast-cell numbers and mast-cell tryptase.
Brockow K; Akin C; Huber M; Scott LM; Schwartz LB; Metcalfe DD
J Allergy Clin Immunol; 2002 Jan; 109(1):82-8. PubMed ID: 11799370
[TBL] [Abstract][Full Text] [Related]
8. Mastocytosis and related entities: a practical roadmap.
Beyens M; Elst J; van der Poorten ML; Van Gasse A; Toscano A; Verlinden A; Vermeulen K; Maes MB; Oude Elberink JNGH; Ebo D; Sabato V
Acta Clin Belg; 2023 Aug; 78(4):325-335. PubMed ID: 36259506
[TBL] [Abstract][Full Text] [Related]
9. Transglutaminase 2 expressed in mast cells recruited into skin or bone marrow induces the development of pediatric mastocytosis.
Ahn YM; Hong GU; Kim SH; Lee HJ; Baek HS; Kim MN; Park KY; Ro JY
Pediatr Allergy Immunol; 2015 Aug; 26(5):438-45. PubMed ID: 25952500
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: Monoclonal mast cell activation syndrome.
Sonneck K; Florian S; Müllauer L; Wimazal F; Födinger M; Sperr WR; Valent P
Int Arch Allergy Immunol; 2007; 142(2):158-64. PubMed ID: 17057414
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience.
Gülen T; Hägglund H; Dahlén B; Nilsson G
Clin Exp Allergy; 2014 Jan; 44(1):121-9. PubMed ID: 24164252
[TBL] [Abstract][Full Text] [Related]
12. Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2021 Apr; 96(4):508-525. PubMed ID: 33524167
[TBL] [Abstract][Full Text] [Related]
13. Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2013 Jul; 88(7):612-24. PubMed ID: 23720340
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine in Systemic Mastocytosis.
Nicolosi M; Patriarca A; Andorno A; Mahmoud AM; Gennari A; Boldorini R; Gaidano G; Crisà E
Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833353
[TBL] [Abstract][Full Text] [Related]
15. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
[TBL] [Abstract][Full Text] [Related]
16. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease.
Sperr WR; Jordan JH; Fiegl M; Escribano L; Bellas C; Dirnhofer S; Semper H; Simonitsch-Klupp I; Horny HP; Valent P
Int Arch Allergy Immunol; 2002 Jun; 128(2):136-41. PubMed ID: 12065914
[TBL] [Abstract][Full Text] [Related]
17. Systemic mastocytosis in adults: 2015 update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2015 Mar; 90(3):250-62. PubMed ID: 25688753
[TBL] [Abstract][Full Text] [Related]
18. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management.
Pardanani A
Am J Hematol; 2012 Apr; 87(4):401-11. PubMed ID: 22410759
[TBL] [Abstract][Full Text] [Related]
19. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management.
Pardanani A
Am J Hematol; 2019 Mar; 94(3):363-377. PubMed ID: 30536695
[TBL] [Abstract][Full Text] [Related]
20. Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.
Valent P; Hartmann K; Schwaab J; Alvarez-Twose I; Brockow K; Bonadonna P; Hermine O; Niedoszytko M; Carter MC; Hoermann G; Sperr WR; Butterfield JH; Ustun C; Zanotti R; Radia DH; Castells M; Triggiani M; Schwartz LB; Orfao A; George TI; Sotlar K; Gotlib J; Reiter A; Horny HP; Arock M; Akin C; Metcalfe DD
J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1999-2012.e6. PubMed ID: 35342031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
